Olstein Capital Management L.P. grew its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 19.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 132,700 shares of the medical equipment provider’s stock after purchasing an additional 21,940 shares during the period. Zimmer Biomet Holdings makes up approximately 2.0% of Olstein Capital Management L.P.’s holdings, making the stock its 5th largest holding. Olstein Capital Management L.P. owned approximately 0.07% of Zimmer Biomet Holdings worth $15,538,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. lifted its stake in shares of Zimmer Biomet Holdings by 4.1% in the 2nd quarter. BlackRock Inc. now owns 17,419,463 shares of the medical equipment provider’s stock valued at $2,236,657,000 after purchasing an additional 679,080 shares in the last quarter. Vanguard Group Inc. lifted its position in Zimmer Biomet Holdings by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 13,380,517 shares of the medical equipment provider’s stock worth $1,718,057,000 after acquiring an additional 339,106 shares in the last quarter. Longview Partners Guernsey LTD lifted its position in Zimmer Biomet Holdings by 17.7% during the 3rd quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock worth $878,958,000 after acquiring an additional 1,128,973 shares in the last quarter. American Century Companies Inc. lifted its position in Zimmer Biomet Holdings by 8.1% during the 3rd quarter. American Century Companies Inc. now owns 4,165,353 shares of the medical equipment provider’s stock worth $487,721,000 after acquiring an additional 311,654 shares in the last quarter. Finally, Northern Trust Corp lifted its position in Zimmer Biomet Holdings by 20.2% during the 2nd quarter. Northern Trust Corp now owns 4,010,274 shares of the medical equipment provider’s stock worth $514,919,000 after acquiring an additional 673,079 shares in the last quarter. 85.36% of the stock is currently owned by institutional investors and hedge funds.

WARNING: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/22/zimmer-biomet-holdings-inc-zbh-shares-bought-by-olstein-capital-management-l-p.html.

Shares of Zimmer Biomet Holdings, Inc. (ZBH) traded down $0.49 during midday trading on Wednesday, hitting $113.07. The stock had a trading volume of 362,664 shares, compared to its average volume of 1,361,683. Zimmer Biomet Holdings, Inc. has a 1-year low of $98.20 and a 1-year high of $133.49. The company has a quick ratio of 0.78, a current ratio of 1.47 and a debt-to-equity ratio of 0.88. The company has a market cap of $22,713.43, a P/E ratio of 13.90, a price-to-earnings-growth ratio of 1.74 and a beta of 1.17.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). The company had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.83 billion. Zimmer Biomet Holdings had a return on equity of 16.29% and a net margin of 8.36%. Zimmer Biomet Holdings’s quarterly revenue was down .8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.79 earnings per share. research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.03 EPS for the current year.

Several research firms recently commented on ZBH. Oppenheimer Holdings, Inc. set a $137.00 price target on Zimmer Biomet Holdings and gave the stock a “buy” rating in a research report on Monday, August 14th. Deutsche Bank AG raised Zimmer Biomet Holdings from a “hold” rating to a “buy” rating and set a $128.00 price target on the stock in a research report on Tuesday, November 14th. BidaskClub lowered Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Zacks Investment Research lowered Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a research report on Monday. Finally, Gabelli began coverage on Zimmer Biomet Holdings in a research report on Thursday, August 24th. They set a “buy” rating and a $142.00 price target on the stock. Four research analysts have rated the stock with a sell rating, seven have issued a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Zimmer Biomet Holdings currently has an average rating of “Hold” and an average price target of $133.71.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.